Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver
Executive Summary
The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.
You may also be interested in...
The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.
Merck & Co. Pauses Enrollment Of Oral Islatravir In PrEP Studies As Bad News Mounts
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.
Merck & Co's Gefapixant Effective In Refractory Cough, But Taste Concerns Remain
Updated results from two Merck & Co Phase III studies, COUGH-1 and COUGH-2, confirm the drug’s efficacy in reducing the frequency of refractory cough and its association with taste disturbances.